The global adrenogenital syndrome treatment market will reach US$12.81 billion in 2023 and increase at a consistent compound yearly growth rate (CAGR) of 5.6% from 2023 to 2033. The reason for this growth is the increased emphasis on cutting-edge therapeutic approaches that enhance patient outcomes. Hormonal abnormalities result from the genetic condition known as AGS, which affects …